四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四 環 醫 藥 控 股 集 團 有 限 公 司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT
SIHUAN PHARMACEUTICAL MADE AN EQUITY INVESTMENT IN SWISS COMPANY SUISSELLE, ACCELERATING THE GLOBAL LAYOUT OF ITS MEDICAL AESTHETIC BUSINESS

The board of directors (the "**Board**") of Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "**Company**" or "**Sihuan Pharmaceutical**", together with its subsidiaries, the "**Group**") is pleased to announce that the Group made an equity investment in Swiss medical aesthetic company Suisselle SA ("**Suisselle**") in September 2025, and the parties have formally entered into an investment and subscription agreement. This collaboration will enhance the strategic relationship between the Group and Suisselle to jointly explore the global medical aesthetic market.

The Group had previously obtained the exclusive distribution rights for the CELLBOOSTER® skin booster in China back in 2022. The current equity investment will further strengthen the long-term cooperative relationship between the two parties. Through this equity investment, the Group will own the permanent exclusive distribution rights of CELLBOOSTER® skin booster products, and will be deeply involved in its operation and development.

Furthermore, following this equity investment of Sihuan Pharmaceutical in Suisselle, the two parties will cooperate to leverage the established platform of Suisselle in Europe to accelerate the promotion and sales of medical aesthetic products, which are independently developed by "**Meiyan Space**", a subsidiary of the Group, in Europe and other overseas markets. Simultaneously, the Group will continue to introduce innovative products from Suisselle and other European companies to enrich the domestic medical aesthetic product matrix. This deployment is highly aligned with the Group's globalization strategy, aiming to build an international medical aesthetic ecosystem covering R&D, production, and sales.

In recent years, the Group has actively advanced the globalization strategy of its medical aesthetic business, having acquired the U.S. medical aesthetic device company Genesis Biosystems in 2021, successfully entering the North American market. The investment in Suisselle is a key step in the Group's globalization strategy of medical aesthetic business, marking the formal completion of the Group's strategic deployment in the two major medical aesthetic markets of Europe and the United States. Looking forward, the Group will continue to rely on the dual drivers of independent R&D and international cooperation to promote high-quality medical aesthetic solutions to benefit broader markets and to create long-term sustainable value for shareholders and investors.

ABOUT SUISSELLE

Suisselle, founded in 2010, is an internationally leading producer of skin booster products. Its core product, the CELLBOOSTER® series skin booster, utilizes the patented CHAC technology, making it the first stabilized complex booster to obtain CE certification, demonstrating significant international competitiveness in technology R&D and product innovation. The company is also concurrently developing PDRN boosters and cell therapy products such as exosomes. Suisselle utilizes cutting-edge innovative and patented CHAC technology to design, develop and produce the safest and most effective professional medical aesthetic products, while adheres to the highest quality standards. The company has expanded its business to 43 countries.

ABOUT CELLBOOSTER® SKIN BOOSTER SERIES

CELLBOOSTER® is an innovative skin booster (European Class III medical device) manufactured in Switzerland. Leveraging its patented CHAC technology, it achieves ingredient stability and efficient delivery, covering multi-dimensional solutions for skin problems:

CELLBOOSTER® SHAPE: Targets localized fat accumulation, edema, and skin laxity, promoting metabolism and drainage;

CELLBOOSTER® GLOW: Focuses on improving hyperpigmentation, uneven skin tone and skin dryness, achieving deep nourishment and anti-oxidative brightening;

CELLBOOSTER® LIFT: Used for skin lifting, wrinkle reduction, and microcirculation improvement, restoring skin firmness and elasticity;

CELLBOOSTER® HAIR: Focuses on scalp health and hair strengthening, preventing hair loss and premature greying.

ABOUT SIHUAN PHARMACEUTICAL

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the "full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses", Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

The Group focuses on medical aesthetic business, and is innovative drive, with nearly ten years of deep cultivation in the medical aesthetic industry, it has created a complete business chain of "raw materials, products, and commercialization" through Meiyan Space in the medical aesthetic field. Its products cover all basic categories of light medical aesthetic, including filling, shaping, support, optoelectronic equipment, and skin management. Its core product sales have occupied an important market share in China. Relying on resource integration and commercialization capabilities, the Group is committed to becoming a leading global provider of medical aesthetic solutions.

LISTING RULES IMPLICATIONS

As at the date of this announcement, to the best knowledge, information and belief of the directors after making all reasonable enquiries, Suisselle and its ultimate beneficial owner(s) are third parties independent from the Company and its connected persons (as defined in the Listing Rules). Therefore, according to Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), the equity investment does not constitute a connected transaction. Besides, as the highest applicable percentage ratio in respect of the equity investment upon consolidated calculation according to Rule 14.07 of the Listing Rules is less than 5%, the equity investment does not constitute a discloseable transaction under Chapter 14 of the Listing Rules.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 13 October 2025

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.